vs
BillionToOne, Inc.（BLLN）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是BillionToOne, Inc.的1.7倍（$140.6M vs $83.5M）。VERACYTE, INC.净利率更高（29.3% vs 6.8%，领先22.4%）。BillionToOne, Inc.同比增速更快（117.4% vs 18.5%）。VERACYTE, INC.自由现金流更多（$48.8M vs $6.5M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
BLLN vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.7倍
$83.5M
营收增速更快
BLLN
高出98.9%
18.5%
净利率更高
VCYT
高出22.4%
6.8%
自由现金流更多
VCYT
多$42.3M
$6.5M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $140.6M |
| 净利润 | $5.7M | $41.1M |
| 毛利率 | 69.9% | 72.5% |
| 营业利润率 | 11.5% | 26.4% |
| 净利率 | 6.8% | 29.3% |
| 营收同比 | 117.4% | 18.5% |
| 净利润同比 | 138.3% | 704.8% |
| 每股收益（稀释后） | $0.10 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNVCYT
| Q4 25 | — | $140.6M | ||
| Q3 25 | $83.5M | $131.9M | ||
| Q2 25 | — | $130.2M | ||
| Q1 25 | — | $114.5M | ||
| Q4 24 | — | $118.6M | ||
| Q3 24 | $38.4M | $115.9M | ||
| Q2 24 | — | $114.4M | ||
| Q1 24 | — | $96.8M |
净利润BLLNVCYT
| Q4 25 | — | $41.1M | ||
| Q3 25 | $5.7M | $19.1M | ||
| Q2 25 | — | $-980.0K | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $-14.9M | $15.2M | ||
| Q2 24 | — | $5.7M | ||
| Q1 24 | — | $-1.9M |
毛利率BLLNVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | 69.9% | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | 52.6% | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率BLLNVCYT
| Q4 25 | — | 26.4% | ||
| Q3 25 | 11.5% | 17.4% | ||
| Q2 25 | — | -4.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | -32.9% | 10.4% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | -4.8% |
净利率BLLNVCYT
| Q4 25 | — | 29.3% | ||
| Q3 25 | 6.8% | 14.5% | ||
| Q2 25 | — | -0.8% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | -38.8% | 13.1% | ||
| Q2 24 | — | 5.0% | ||
| Q1 24 | — | -1.9% |
每股收益（稀释后）BLLNVCYT
| Q4 25 | — | $0.50 | ||
| Q3 25 | $0.10 | $0.24 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-1.47 | $0.19 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $362.6M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $1.3B |
| 总资产 | $327.5M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | $195.2M | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
总债务BLLNVCYT
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNVCYT
| Q4 25 | — | $1.3B | ||
| Q3 25 | $-239.5M | $1.3B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $-242.9M | $1.2B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
总资产BLLNVCYT
| Q4 25 | — | $1.4B | ||
| Q3 25 | $327.5M | $1.4B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $48.8M |
| 自由现金流率自由现金流/营收 | 7.7% | 34.7% |
| 资本支出强度资本支出/营收 | 8.8% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.42× | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流BLLNVCYT
| Q4 25 | — | $52.6M | ||
| Q3 25 | $13.8M | $44.8M | ||
| Q2 25 | — | $33.6M | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | — | $24.5M | ||
| Q3 24 | — | $30.0M | ||
| Q2 24 | — | $29.6M | ||
| Q1 24 | — | $-9.0M |
自由现金流BLLNVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | $6.5M | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率BLLNVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | 7.7% | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度BLLNVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | 8.8% | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率BLLNVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 2.42× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
